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The Journal of Immunology
Microcrystalline Tyrosine and Aluminum as Adjuvants in
Allergen-Specific Immunotherapy Protect from IgE-Mediated
Reactivity in Mouse Models and Act Independently of
Inflammasome and TLR Signaling
Deborah S. Leuthard,* Agathe Duda,† Sandra N. Freiberger,* Sina Weiss,*
Isabella Dommann,* Gabriele Fenini,* Emmanuel Contassot,*,† Matthias F. Kramer,‡,x
Murray A. Skinner,x Thomas M. Ku¨ndig,*,† Matthew D. Heath,x and Pa˚l Johansen*,†
Allergen immunotherapy (AIT) is the only modality that can modify immune responses to allergen exposure, but therapeutic cov-
erage is low. One strategy to improve AIT safety and efficacy is the use of new or improved adjuvants. This study investigates
immune responses produced by microcrystalline tyrosine (MCT)–based vaccines as compared with conventional aluminum
hydroxide (alum). Wild-type, immune-signaling–deficient, and TCR-transgenic mice were treated with different Ags (e.g., OVA
and cat dander Fel d 1), plus MCTor alum as depot adjuvants. Specific Ab responses in serum were measured by ELISA, whereas
cytokine secretion was measured both in culture supernatants by ELISA or by flow cytometry of spleen cells. Upon initiation of
AIT in allergic mice, body temperature and further clinical signs were used as indicators for anaphylaxis. Overall, MCTand alum
induced comparable B and T cell responses, which were independent of TLR signaling. Alum induced stronger IgE and IL-4
secretion than MCT. MCT and alum induced caspase-dependent IL-1b secretion in human monocytes in vitro, but inflammasome
activation had no functional effect on inflammatory and Ab responses measured in vivo. In sensitized mice, AIT with MCT-
adjuvanted allergens caused fewer anaphylactic reactions compared with alum-adjuvanted allergens. As depot adjuvants, MCT
and alum are comparably effective in strength and mechanism of Ag-specific IgG induction and induction of T cell responses. The
biocompatible and biodegradable MCT seems therefore a suitable alternative adjuvant to alum-based vaccines and AIT. The
Journal of Immunology, 2018, 200: 3151–3159.
A
llergy is a leading cause of chronic illness (1), with social
and economic impacts on life quality and health care
costs (2). Allergen immunotherapy (AIT) is disease-
modifying and reduces symptoms and medication use in allergic
rhinoconjunctivitis and asthma (3), but because of ignorance of
efficacy, potential side effects, and a long treatment duration,
,10% of allergy patients chose to receive AIT (4). Hence, safer or
more effective AIT using alternate administration routes, better
allergens, and better adjuvants (5) is needed.
Adjuvants enhance Ag-specific immune responses in vaccines
and AIT. The most used adjuvant is aluminum hydroxide (alum),
which was introduced empirically in vaccines a century ago (6).
Suggested mechanisms of action are depot formation (7), en-
hancement of Ag uptake by APCs (8), and NLRP3 inflammasome
activation (9–13). In animals and humans, alum mediates a Th2
immune response (7), which counteracts recognized therapeutic
mechanisms of AIT. Furthermore, there are concerns with respect
to alum accumulation in tissues in AIT (14). Although alum has
remained the adjuvant of choice across the broader vaccine scope,
the nonessential amino acid L-tyrosine was developed as an al-
ternative depot platform for delivering AIT as well as other vac-
cine Ags. This proprietary depot adjuvant is now referred to as
microcrystalline tyrosine (MCT), which reflects its physico-
chemical properties, such as a distinct crystalline particle size and
needle-like morphology. During processing steps, MCT is either
coprecipitated with the candidate Ag or the Ag is adsorbed to the
preformed MCT. MCT products are marketed for use in AIT,
some of which are licensed (15), and MCT has been shown to
facilitate allergen-specific IgG4 Ab production as well as IL-10
secretion from T cells (16–19). This study compares MCT and
alum in mouse models to better understand their mode of action as
adjuvants in AIT and other vaccines.
Materials and Methods
Materials
Grade V OVA and low-endotoxin OVA were from Sigma-Aldrich (Buchs,
Switzerland). Alhydrogel 2% gel (alum) was from Brenntag (Fredrikssund,
Denmark). Cat fur allergen extract was purchased from Stallergenes AG
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(Dietlikon, Switzerland). Birch pollen allergen extract (440 mg/ml protein,
from 24.8% Bet v 1) and MCT (40 mg/ml) was provided by Allergy
Therapeutics (Worthing, U.K.). Recombinant Fel d 1, the major cat fur
allergen, was kindly provided by F. Thoms from the University of Zurich.
Because allergen extracts are not rigorously standardized, we cannot
compare how amounts of extracts in different units (IU, IR) compare with
allergen content when comparing extracts from different sources.
Animals
BALB/c (H2d) andC57BL/6 (H2b)micewere purchased fromEnvigo (Horst, the
Netherlands). All gene-modified mice were bred at the Biologisches Zentrallabor
of the University Hospital Zurich (Zurich, Switzerland) or at the Laboratory for
Animal Science at the University of Zurich. Mice deficient in either MyD88, TIR
(Toll/IL-1R) domain-containing adapter inducing IFN-b (TRIF), TLR4, or
NALP3 were obtained from the Swiss Immunological Mutant Mouse Reposi-
tory. Mice deficient for NALP3 and ASC (20) were originally from J. Tschopp
(Biochemistry Institute, University of Lausanne, Switzerland) (21) and Gen-
entech (San Francisco, CA), respectively (21). RAG1-deficient CD8 TCR
transgenic OT-I mice were originally from Taconic Biosciences (Ry, Denmark).
CD4 TCR transgenic OT-II mice were obtained from the Swiss Immunological
Mutant Mouse Repository. All animals were kept and the experiments per-
formed under specific pathogen-free conditions. The experiments were autho-
rized by the cantonal veterinary office of Zurich and performed in accordance
with Swiss animal law and regulations (animal experiment authorization num-
bers: ZH200/2014 and ZH 52/2016).
Vaccine preparations
MCT vaccines were prepared according to an experimental protocol from
Allergy Therapeutics. MCT or alum was rigorously vortexed (1 min) at room
temperature to resuspend the particles. The required volumes of adjuvant and
PBS were then transferred into sterile Ag-containing Eppendorf vials. The
mixtures were again vortexed and left for 1 h at room temperature for complete
protein adsorption.
Immunization
Mice were immunized with vaccine preparations by injection of 100 ml s.c.
(scruff of the neck) or i.p. Prior to each injection, vaccine preparations were
thoroughly mixed. The vaccines were composed of OVA adsorbed to MCT or
alum. Control mice received soluble OVA or PBS or were left untreated.
Immunization doses were 0.01–100 mg of OVA, 0.27–2.7 mg of MCT, and
0.1–1 mg of alum. The number of immunization sessions was one to three and
the interval between two sessions was 14 d if not otherwise specified.
Mice were tail bled, and the collected sera were analyzed by ELISA for
OVA-specific Abs. Spleens were harvested at the end of the experiments and
analyzed for OVA-specific CD8 T cell proliferation or cytokine production
by flow cytometry or ELISA after in vitro restimulation with OVA.
Adoptive T cell transfer and testing of CD4 and CD8 T cell
responses
C57BL/6 mice received an i.v. transfer of 5 3 105 OT-I and 106 OT-II cells
through the tail vein. One and eight days later, the mice were immunized s.c.
with 100 mg OVA with MCT or alum. On day 15, spleens were isolated for
further analysis of OVA-specific T cell responses by flow cytometry and ELISA.
Analysis of serum Abs by ELISA
Sera were analyzed for Ag-specific Abs by ELISA (22–24). Briefly, 96-well
plates were coated with OVA (4 mg/ml), cat fur allergen extract (1 IR/ml),
recombinant Fel d 1 (1 mg/ml), or birch pollen allergen extract (30 mg/ml) in
a NaHCO3/Na2CO3 buffer at pH 9.4 for IgG analysis. For IgE, the plates were
coated with anti-IgE mAb (Bio-Rad Laboratories, Cressier, Switzerland). After
overnight incubation at 4˚C and blocking with 2.5% nonfat dried skimmed cow
milk in PBS–Tween 20, sera diluted in PBS–Tween 20 were added and in-
cubated for 2 h. After washing the plate, biotinylated anti-murine Abs (BD
Pharmingen, Basel, Switzerland) were added for IgG analysis, and bio-
tinylated Ag was added for IgE analysis. The plates were then incubated
with streptavidin-conjugated HRP (BioLegend, Koblenz, Germany) and
developed with tetramethylbenzidine substrate (BioLegend). Absorbance
was read at 450 nm using a BioTek plate reader. The Ab titers were defined
as the last serum dilution giving an ELISA OD higher than the mean of
naive sera plus thrice the SD of the mean.
Restimulation of splenocytes in vitro for analysis of cytokine
secretion
Spleens were harvested and crushed through a cell strainer. After lysis of
erythrocytes in RBC lysis buffer (Sigma), splenocytes were prepared at
5 3 105 cells/well in RPMI-1640 complemented with FBS, glutamine, and
antibiotics. The cultures were incubated with Ag at 37˚C for 20 (IL-2,
TNF-a) or 96 (IL-4, IL-10, IFN-g) h. Cytokine secretion into the
supernatant was measured by Ready-SET-Go! ELISA according to the
manufacturer (Invitrogen, distributed by Thermo Fisher Scientific, Zug,
Switzerland).
Flow cytometry for analysis of T cell responses
Splenocytes were prepared as described above. For analysis of SIINFEKL-
specific CD8 T cell proliferation, the cells were Fc receptor blocked with
anti-CD16/32 and stained with fluorescent anti-CD8 and anti-CD44 Abs
and PE-labeled H2Kb-SIINFEKL (ProImmune, Oxford, U.K.). For analysis
of intracellular cytokine production, the cells were incubated overnight
with 10 mg/ml OVA and 2.5 mg/ml brefeldin A (Sigma) for the last 4 h.
After washing and Fc receptor blocking, the cells were stained with
anti-CD4, anti-CD8, and anti-CD44; fixed in 4% paraformaldehyde; per-
meabilized in Perm/Wash (BD Biosciences); and stained with anti–IFN-g and
anti–TNF-a Abs. All stainings were done in cold PBS supplemented with 2%
FBS and protected from light. All staining Abs were from eBioscience or
BD Pharmingen. The stained cells were acquired on BD FACSCanto II
(BD Biosciences) and analyzed with FlowJo (FlowJo, Ashland, OR).
Allergen immunotherapy
In a model of allergic anaphylaxis, mice were sensitized by four weekly i.p.
injections of 1.0 IR units of cat dander allergen adsorbed to 0.5 mg alum
(25, 26). Four weeks after the last injection, mice received AIT by three
fortnightly s.c. injections of 25 mg recombinant cat (Felis domesticus)
major allergen Fel d 1 adsorbed to either 2 mg MCT or 1 mg of alum. The
range of adjuvant concentrations in all experiments was based on con-
centrations in clinical use. A control group was sensitized only. Mice were
tail bled at different time points, and sera were analyzed for allergen-
specific Abs.
Alternatively, mice were sensitized by i.p. injections of 5.8 mg birch
pollen allergen extract on 0.5 mg alum. Starting 2 wk after the last sen-
sitization, mice received AIT consisting of three fortnightly or five weekly
s.c. injections of birch pollen allergen extract adsorbed to 2.0 mg MCT.
The cumulative dose of birch pollen allergen extract protein was 264 mg
(from 65.47 mg major allergen Bet v 1)—i.e., 3 3 88 mg (fortnightly)
or 5 3 52.8 mg (weekly). One group of mice received weekly
dose-incrementing AIT (10, 20, 40, 84, and 110 mg). Control mice were
sensitized only.
Allergen provocation test for analysis of anaphylaxis
Three weeks after the last AIT session, mice were challenged by an i.p.
injection of 10 IR cat dander allergen extract (or 52.4 mg birch pollen
allergen extract) to measure AIT-mediated protection against anaphylaxis.
Before the challenge, and at 20–30 min intervals thereafter, body tem-
perature was measured rectally with a digital Thermalert TH-5 ther-
mometer with a RET-3 probe (Physitemp, Huron, NJ). A time–temperature
curve was plotted and the area under curve (AUC) was calculated in
GraphPad Prism v7.02 from GraphPad Software (La Jolla, CA). One day
after the challenge, mice were euthanized and spleens were harvested for
restimulation of splenocytes and analysis of cytokine secretion.
In vitro assessment of inflammasome activation by MCT in
human monocytes (THP-1)
THP-1 cells were pretreated with 3 mM PMA for 3 d followed by 24 h of
incubation with 50 ng/ml ultra-pure LPS. The cells were then treated for
6 h with different doses of MCT or MCT plus zVAD. The concentration of
IL-1b was measured in the culture supernatants by ELISA (Invitrogen).
To determine the percentage of cell death, a lactate dehydrogenase cyto-
toxicity assay was used as described by the manufacturer (Pierce; Thermo
Fisher Scientific). The proform and the mature form of IL-1b were sep-
arated by Western blot, and nigericin was used as positive control.
Analysis of local and systemic inflammatory responses upon
injection of adjuvants
Mice were injected i.p. with PBS, alum (1 mg), or MCT (2 mg) in 100 ml PBS.
After the injection, a peritoneal lavage was done. Peritoneal cells were analyzed
by flow cytometry using fluorescent Abs against CD11b, CD4, CD8, and B220.
Statistics
Statistical analysis was done with GraphPad Prism v7.02. Two treatment
groups were compared using nonparametric, two-tailed Mann–Whitney
U tests. More groups were compared using Kruskal–Wallis tests with Dunn’s
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post hoc test for multiple comparisons. Time–temperature curves were in-
tegrated using the baseline temperature for the calculation of the AUC.
Two-way parametric ANOVA was applied to test the statistical differences
between the different treatment groups. Prior to this, normally distributed
data were confirmed using the D’Agostino and Pearson normality test.
Significant differences were annotated with asterisks: *p, 0.05, **p, 0.01.
Results
MCT enhances B and T cell responses in mice
To measure the threshold for stimulation of Ag-specific Ab re-
sponses, mice were first immunized with low doses of OVA. After a
single injection of 0.01 mg OVA, Ag-specific IgG1 Ab responses
were observed in all mice that received OVA-alum (Fig. 1A),
whereas no response was measured after 0.01 mg OVA-MCT or
OVA-PBS. Upon a booster immunization on day 28, OVA-specific
IgG1 was observed within 2 wk in one out of three mice receiving
OVA-MCT. At 0.1 mg OVA, Ag-specific IgG1 was observed in all
mice that received a single injection of either OVA-alum or
OVA-MCT but not in the adjuvant-free OVA-PBS control. Similar
results were observed for OVA-specific IgG2a (data not shown).
Mice that received 0.1 mg OVA were given a second booster
immunization and were euthanized 6 d later for Ag restimulation
of splenocytes in culture. Adjuvanted vaccines enhanced IL-2,
IFN-g, IL-4, and IL-10 cytokine secretion, with significantly
higher IL-4 secretion in cells from alum-treated mice (Fig. 1B).
Cells from mice immunized with OVA-PBS did not produce cy-
tokines. The reduction of the MCT adjuvant dose from 2 to 0.4%
did not affect the IgG1 responses notably (data not shown), but an
earlier onset of IgG2a production was observed for the highest
MCT dose; hence, 2% MCT was used in the subsequent studies.
Mice were then immunized thrice with 1 or 100 mg OVA for
more complete analysis of Ab isotypes and their subclasses and
kinetics (Fig. 1C). MCT and alum facilitated almost identical IgG,
IgG1, and IgG2b responses. Only for IgG2a and IgG3 did 1 mg
OVA-alum trigger a slightly earlier onset of the response than
MCT. However, the end point responses after 6 wk were similar
for MCT- and alum-based vaccines. At 100 mg OVA, all IgG
kinetics and titers were comparable. OVA-specific IgE titers were
lower with MCT than with alum at 100 mg (p = 0.015 by two-way
ANOVA).
MCT- and alum-based vaccines trigger comparable CD4 and
CD8 T cell responses in mice
In order to facilitate the analysis of the effect of MCT and alum
adjuvants on the stimulation of T cell responses, C57BL/6 mice
were adoptively transferred lymphocytes from syngeneic OT-I and
OT-II mice prior to immunization on days 0 and 7, with 100 mg
OVA-MCT or OVA-alum. On day 14, spleens were harvested and
analyzed by flow cytometry and ELISA for T cell proliferation
and cytokine secretion.
OVA-MCT and OVA-alum significantly stimulated proliferation
of CD8 T cells specific for the H2Kb-restricted OVA Ag OVA aa
257–264 (SIINFEKL) (Fig. 2A, p , 0.05 by Kruskal–Wallis).
The percentages of IFN-g–producing CD8 T cells and IFN-g–
and TNF-a–double-producing cells were higher in immunized
mice than in untreated controls (p , 0.05), with no significant
FIGURE 1. Immunogenicity testing of tyrosine- and alum-based vaccines in BALB/c mice. (A) Mice (n = 3–4) were injected with 0.01 or 0.1 mg OVA on alum
(black symbols), MCT (open symbols), or in PBS (dashed lines) on days 0 and 28, and Ab titers were measured on days 28 and 42. Titration curves for individual
mice are illustrated. (B) After a third injection with OVA 0.1 mg on day 56, splenocytes were harvested on day 62 and restimulated with OVA for analysis of
cytokine secretion (mean + SD). (C) Mice (n = 5) were immunized with 1 (left) or 100 (right) mg OVA on days, 0, 14, and 28; total IgG, IgG1, IgG2a, IgG2b, IgG3,
and IgE Abs were determined (mean 6 SEM). The latter experiment is representative of three independent experiments with comparable results.
The Journal of Immunology 3153
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difference between MCT and alum (Fig. 2B). Similar effects were
observed in CD4 T cells, with a positive effect of adjuvants
(Fig. 2C). After restimulation of splenocytes in vitro with OVA
protein or with MHC class I– or MHC class II–restricted OVA
peptides, Ag-specific IFN-g secretion from CD8 and CD4 T cells
from immunized mice occurred (Fig. 2D), with no statistical
difference between OVA-MCT and OVA-alum. C57BL/6 mice
were also directly immunized to compare the capacity of the two
adjuvants to trigger endogenous T cell responses (data not shown).
Compared with nonimmunized mice, both OVA-MCT and
OVA-alum induced significant and comparable CD8 T cell pro-
liferation as well as IFN-g and TNF-a production from CD8 and
CD4 T cells.
AIT with MCT-based vaccines reduced anaphylactic reaction
in cat dander allergen-sensitized mice
In order to test the relative strength of MCT and alum as adjuvants
in allergy vaccines, the AITefficacy was assessed in a mouse model
of cat allergy (Fig. 3A). BALB/c mice were sensitized to cat
dander allergens, then treated with recombinant Fel d 1 allergen
mixed with MCT or alum. AITwith MCT, but not with alum, caused
a decrease in cat-specific IgE antibodies (Fig. 3B). Fel d 1–specific
IgG2a Ab titers increased after AIT and were comparable in
MCT- and alum-treated mice. The titers were significantly higher
than in sensitized control mice (p , 0.0.01). Four weeks after the
third AIT shot, mice were i.p. challenged with cat dander allergen
extract. Nonsensitized mice showed no reactions (Fig. 3C), whereas
severe anaphylaxis was observed in sensitized mice having received
no AIT. Anaphylaxis manifested as hypothermia within 20 min, with
an average body temperature drop of 3.5˚C (from 38.0 to 34.5˚C).
Moreover, hypothermia was accompanied by apathy, a hunched
back, and piloerection. Sensitized mice that received AIT showed
notably less signs of anaphylaxis, including significantly reduced
hypothermia, as compared with mice that did not receive AIT
(Fig. 3C). Within 60–80 min after challenge, treated mice recovered
from the transient and moderate anaphylaxis, whereas sensitized
animals still exhibited anaphylaxis symptoms and a temperature
∼2˚C below the prechallenge level. When calculating the AUC for
the body temperature drop, AIT with either MCT or alum adju-
vants proved strongly protective (Fig. 3C, right panel; p = 0.01).
No significant difference between alum- and MCT-treated mice
was found. One week after the challenge, mice were euthanized
and the splenocytes were restimulated with Fel d 1. AITwith alum
and MCT equally resulted in significant IL-2, IFN-g, and IL-10
secretion as compared with sensitized controls (Fig. 3D).
The efficacy of AIT with MCT was also performed in mice
sensitized to birch pollen allergens (Table I). A cumulative aller-
gen dose of 264 mg was split on five weekly or three biweekly
injections. One group of mice received the five doses in a dose-
increasing pattern. Upon AIT, allergen-specific IgG1 and IgG2a
Ab responses were induced, especially after weekly AIT. Upon a
systemic challenge with an allergen, sensitized controls reacted
with severe anaphylactic hypothermia, whereas weekly AIT
caused overall sufficient protection (Table I). The strongest pro-
tection was achieved after dose-increasing AIT.
Allergic adverse events of AIT with MCT versus alum in a
mouse model of anaphylaxis
One of the side effects of AIT in allergic patients is the risk of local
or systemic allergic reactions because of the allergen-containing
AIT itself. To test the risk of anaphylaxis of AIT with MCT
or alum, mice were sensitized to OVA as described above by four
i.p. injections, then given a single s.c. AIT treatment with OVA. The
body temperature in mice that received OVA-alum dropped from
37.5 to 31.8˚C within 30 min (Fig. 4A), whereas OVA-MCT
caused a drop to 33.5˚C. When the AUC for the time–temperature
FIGURE 2. T cell response after MCT- or alum-adjuvanted immunization. C57BL/6 mice (n = 5) were adoptively transferred with OT-I and OT-II cells
and immunized with 100 mg OVA on MCT (gray bars) or alum (black bars) 1 and 8 d later (individual mice are indicated). On day 15, spleen cells were
analyzed by flow cytometry. (A) Dot blots and histograms show SIINFEKL-specific CD8 T cell activation (CD44) and proliferation (H2Kb pentamer).
Frequencies of IFN-g–producing and IFN-g– and TNF-a–double-producing CD8 T cells (B) and CD4 T cells (C). (D) Splenocytes were also restimulated
in vitro with MHC class I–restricted OVA aa 257–264 (SIINFEKL), MHC class II–restricted OVA aa 323–339, or OVA protein, and IFN-g in culture
supernatants was measured by ELISA. Mean 6 SD of means are illustrated. The experiment is representative of two independent experiments with
comparable results. *p , 0.05, **p , 0.01.
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function was calculated, AIT with MCT caused significantly
(p = 0.012) less anaphylaxis than AIT with alum (Fig. 4B).
The adjuvant properties of MCT are independent on TLR
signaling
Whereas alum has been shown to act independently of TLR sig-
naling, it is unknown if MCT used TLR for its adjuvant effects.
To this end, TLR signaling–deficient mice were immunized twice
with OVA on MCT or alum. The adjuvant effects of MCT or alum
were not compromised in the absence of MyD88 signaling, as
production of all IgG subclasses was stimulated by both
OVA-MCT and OVA-alum (Fig. 5A). Alum, but not MCT, pro-
moted anti-OVA IgE production in wild-type mice, whereas no
IgE was observed in MyD88- or TLR4-deficient mice. Ag-specific
IgG Ab responses were also not compromised in TRIF-deficient
mice immunized with OVA-MCT (Fig. 5B).
MCT induces caspase-dependent IL-1b secretion in vitro
Because alum has been shown to activate the inflammasome, we
investigated whether MCT also activated inflammasome. Firstly,
human monocyte cells (THP-1) were incubated with various doses
of MCT in the presence or absence of the pan-caspase inhibi-
tor zVAD, which inhibits inflammasome-related cleavage of
caspase-1 and subsequent maturation of pro–IL-1b to the se-
creted IL-1b. MCT caused secretion of IL-1b, and this was
inhibited by zVAD, suggesting caspase dependency (Fig. 6A).
IL-1b in the supernatant was not a result of MCT-induced cell
death because cell death caused by MCT was not significantly
different from untreated cells (Fig. 6B). As the IL-1b ELISA
does not distinguish between pro–IL-1b and cleaved IL-1b, the
culture supernatant was assessed by Western blot (Fig. 6C). In
untreated THP-1 cells, only small amounts of pro–IL-1b were
detected, whereas in MCT-treated cells, mature IL-1b was de-
tected, and the secretion of the cleaved IL-1b was inhibited by
zVAD. MCT- and alum-based vaccines caused similar acute but
transient inflammatory responses.
One suggested adjuvant mechanism of alum has been the pro-
motion of inflammatory responses at the injection site (9–11, 27);
the adjuvant is injected i.p., and the inflammatory infiltrate is
assessed by peritoneal lavage. Both alum and MCT caused infil-
tration of CD11b– and Ly6G–double-positive neutrophils (Fig. 6D,
6E) and of CD11b– and SiglecF–double-positive eosinophils
FIGURE 3. Immunotherapy of cat dander allergy. BALB/C mice (n = 5) were sensitized by weekly injections of cat fur allergen extract and received AIT
with recombinant Fel d 1 allergen on alum (red) or MCT (blue) thrice s.c., as indicated (A). Finally, the mice were challenged with cat fur allergen extract to
test tolerance to anaphylaxis. (B) Cat fur allergen-specific IgE (left) and Fel d 1–specific IgG2a (right) Ab titers were measured in sera before and after
sensitization and AIT. (C) After challenge, changes in the body temperature were measured as an indicator for anaphylaxis. Left, Rectal body temperature
as function of time after challenge. Right, Integrated AUC with baseline 38˚C for the body temperature curves. (D) Splenocytes were restimulated with rFel
d 1 for 20 h (IL-2) or 96 h (IFN-g and IL-10), and cytokines were measured in the supernatants by ELISA. Abs are illustrated as mean 6 SEM, and other
results are illustrated as mean 6 SD.
Table I. Effect of MCT-based birch allergen AIT on specific Abs and tolerance to a birch allergen challenge
Readout
Number of AIT Sessions
No AIT 3 5 5-incra
IgE 857 1183 1284 1256
IgG1 (3 105) 10.9 10.3 21.4 18.9
IgG2a (3 103) 1.7 9.3 15.4 16.9
Hypothermia, AUCb 1265 1292 NS 928 NS 437*
Mice (five to six per group) sensitized with birch pollen allergen extract received s.c. AITwith the same allergen adsorbed on MCT. The allergen dose of 264 mg birch pollen
allergen (65.47 mcg Bet v 1) was split on three or five doses given with 14- or 7-d intervals. End point birch pollen allergen extract–specific Ab titers were analyzed by ELISA.
Protection against anaphylaxis after a systemic challenge with birch pollen allergen was determined by measuring the change in body temperature upon challenge, and the
temperature–time AUC was calculated with a baseline temperature of 38˚C and with 4 h of assessment time.
aThe allergen dose given was increasing for each AIT session: 10 (2.48), 20 (4.96), 40 (9.92), 84 (20.83), and 110 (27.28) mcg with regard to total protein (Bet v 1 content in
parentheses).
bAUC was calculated for time–temperature curves after challenge with birch pollen allergen extract (baseline: 38˚C, test time: 4 h).
*p , 0.01 as compared with no AIT.
NS, not significant as compared with no AIT (ANOVA).
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(Fig. 6F), as assessed by flow cytometry. The effect of MCT lasted
for at least 24 h. The effect of alum peaked at 4 h and decreased by
50% at 24 h. Moreover, resident F4/80-positive macrophages were
reduced from 70% of all CD11b cells to ,5% after administration
of alum or MCT, and this effect lasted at least 24 h (Fig. 6G).
Following the reduction of F4/80 macrophages in the peritoneal
exudate cells, a marked drop in MHC class II– and CD11b–
double-positive cells was also observed (Fig. 6H). A slight in-
crease in CD11c–CD11b double-positive dendritic cells (DCs)
was observed in the peritoneal exudate at 24 h postinjection
(Fig. 6I). The inflammasome dependence of the inflammatory
reactions in vivo was assessed in mice deficient for the NALP3
inflammasome (Fig. 6J). Alum or MCT were administered as
above, and the inflammatory responses were analyzed 24 h post-
injection. Neither peritoneal neutrophil nor F4/80 macrophage
levels were affected by NALP3 deficiency. Although the count of
CD11c DCs was lower in NALP3-deficient mice than in wild-type
mice, the administration of MCT or alum increased the frequency
of DCs in the peritoneal exudate.
B and T cell responses to MCT- and alum-based vaccines are
not dependent on or affected by inflammasome activation
Whether inflammasome activation affects the production of Abs by
B cells or the secretion of cytokines by T cells was tested in
ASC-deficient mice, which have nonfunctional inflammasomes. Mice
were injected on days 0, 14, and 26 with 0.1mg OVA onMCTor alum.
Neither MCT nor alum required inflammasome activation for its ad-
juvant effect regarding the stimulation of Ag-specific IgG or IgE Ab
responses, as illustrated in sera from day 42 (Fig. 7A). When day-48
splenocytes were restimulated in vitro with OVA and cytokines were
measured in the culture supernatants, the results further revealed that
T cell–mediated IFN-g and IL-2 secretion were not compromised in
the absence of a functional inflammasome (Fig. 7B). Neither MCT nor
alum triggered Ag-specific secretion of IL-17a or TNF-a (Fig. 7B).
Discussion
Along with its nearly century-long application as an adjuvant in
conventional childhood and seasonal vaccines, alum is well
established in licensed AIT (28, 29), and it represents the current
state of the art in further AIT development. The recent decades
have seen many attempts to find alternatives to alum in AIT and
vaccination. Especially in AIT, MCT has shown clinical potential
(28–31). Whereas the adjuvancy of alum was first explained by its
depot effect—prolonged immune exposure resulting in sustained
Ab titers (13, 32)—the adjuvancy of MCT is less understood.
In this article, we report the first direct comparative study, to our
knowledge, of alum and MCT in AIT. Immunological properties
and mechanisms of action of the adjuvants were studied in mice.
Our study demonstrates that both MCT and alum enhanced IgG
Ab responses to different allergens, such as OVA, birch pollen, and
cat dander. Although a single injection with alum-adjuvanted
allergen was slightly more immunogenic than MCT-adjuvanted
allergen, MCT induced comparable high and sustained IgG Ab
titers when the injection was repeated. Multiple MCT injections
FIGURE 4. Safety testing of MCT- and alum-based vaccines in mice.
BALB/C mice (n = 5) were sensitized by four weekly i.p. injections of
OVA adsorbed on alum. Four weeks later, the mice received a single s.c.
AIT with OVA on MCT (open circles and bars) or on alum (closed circles
and bars). Body temperature changes are illustrated as a function of time
after AIT (A) and integrated as AUC (B). The experiment is representative
of two independent experiments with comparable results.
FIGURE 5. Immunogenicity testing in mice deficient in TLR signaling. (A) C57BL/6 wild-type mice as well as syngeneic MyD88- and TLR4-deficient
mice were immunized with 40 mg OVA-MCT (gray circles) or 40 mg OVA-alum (black circles) on days 0 and 14. Abs in blood were measured by ELISA.
(B) C57BL/6 mice as well as syngeneic TRIF-deficient mice were immunized with 10 mg OVA-MCT on days 0 and 14. Abs in blood were measured by
ELISA. The experiment is representative of two independent experiments with comparable results and with four to six mice per group.
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produced less IgE than did alum-based vaccines, confirming earlier
reports (33), and this immunological profile formed part of the
rationale for the development of MCT-based AIT. By conse-
quence, the allergen-specific IgE-to-IgG2 ratio was higher with
MCT-based than with alum-based AIT. In humans, the IgE-to-IgG4
ratio is a biomarker for effective AIT (34). The lower IgE response
with MCT may be explained by less IL-4 secretion or stronger
secretion of counteracting IFN-g, hence a less Th2-skewed immune
response (35, 36). Although MCT may not be characterized as a
Th1-polarizing adjuvant, experiments in mice suggested that MCT
triggered stronger Th1-associated immune responses than alum,
especially at higher Ag doses. Particularly, MCT facilitated the
recruitment of DCs and elicitation of CD8 T cell responses with
associated IFN-g and TNF-a production. These data are in line
with studies demonstrating protective efficacy in influenza and
malaria mouse models (17–19) and are favorable for long-term
clinical tolerance following AIT (37, 38). Other important bio-
markers for the monitoring of AIT are regulatory T cells and IL-10
(34). In the current study, alum and MCT resulted in similar IL-10
secretion from lymphocytes in vitro. The cellular analysis also
suggested that alum and MCT trigger comparable CD4 T cell
responses, whereas MCT triggers stronger CD8 T cell responses
associated with Th1. Most importantly, the current study confirmed
the benefit of MCT in AIT, which caused reduction in allergen-
specific IgE and increased IgG1 and IgG2a and protection in the
murine model of allergic anaphylaxis.
Alum can activate specific innate signaling pathways such as the
NALP3 inflammasome (9–11). We could also demonstrate that
MCT caused inflammasome activation in vitro and that MCT and
alum produced similar inflammatory responses in vivo. Both
adjuvants were characterized by immediate exudation of neutro-
phils and eosinophils. The current study is the first, to our
knowledge, to characterize such inflammatory responses for MCT.
Although many innate reactions are important for the onset of
adaptive immunity, the role of inflammasome activation in im-
munization and AIT has not been precisely defined. We therefore
FIGURE 6. Assessment of inflammasome activation and other inflammatory reactions in vivo and in vitro. (A–C) THP-1 human monocytes were in-
cubated with various doses of MCT in the presence or absence of zVAD. IL-1b secretion (A) and viability (B) were measured by cytokine and lactate
dehydrogenase cytotoxicity ELISA, respectively, in supernatants. (C) Pro–IL-1b and cleaved IL-1b were separated by Western blot using nigericin as a
positive control. For the sake of presentation, the blot was cropped and spliced as indicated with the vertical white line, excess sample replicates being
omitted. (D) MCT, alum, or PBS were injected i.p. in mice, and cell populations in the peritoneal lavage were analyzed by flow cytometry as indicated.
Infiltration of CD11b– and Ly6G–double-positive neutrophils (E), CD11b– and SiglecF–double-positive eosinophils (F), F4/80-positive macrophages (G),
MHC class II– and CD11b–double-positive cells (H), and CD11c–CD11b double-positive DCs (I) were measured 4 h (open bars) and 24 h (closed bars)
postinjection. The results with wild-type mice are representative of three independent experiments. (J) Percentage of neutrophils, macrophages, and DCs in
wild-type versus NALP3 inflammasome knockout mice.
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tested if the immunogenicity of MCT- and alum-based vaccines
was affected in mice deficient for ASC, the key common adaptor
protein in inflammasome activation. Neither Ag-specific IgE nor
IgG Ab responses were ASC dependent, and similar results have
been reported for alum in mice deficient in IL-1R (27) or NLRP3
(12). Hence, although alum and MCT may activate the inflam-
masome, this does not affect the adaptive immune response
needed for Ab production in AIT.
Most modern adjuvants act on APCs through direct ligation of
pathogen recognition receptors such as TLRs, retinoic acid–inducible
RLRs, nucleotide-binding NLRs, C-lectin CLRs, and cytosolic DNA
sensors (39). Alternatively, the pathogen recognition receptor acti-
vation could be a secondary reaction following an unknown
inflammatory trigger. We demonstrated that neither MCT nor alum
exerted its adjuvant properties via TLRs because Ab responses were
not affected by preventing signal transmission through MyD88,
TRIF, or TLR4. Robust Ab responses to alum-based vaccines were
previously demonstrated in MyD88- and TRIF-deficient mice (40).
Hence, MCT shares many of the immunological properties of alum,
albeit harboring different physicochemical properties, such as particle
size, morphology, adsorption characteristics, and local pharmacoki-
netics (41). Alum is usually an oxyhydroxide salt (boehmite) with a
positive surface charge at pH 7.4 and a spherical dimension in the
nanometer range. Self-associating MCT form needle-like crystals in
the micrometer range. The different isoelectric properties may also
influence the Ag release from the adjuvants. Alum and protein Ags
are typically associated by a ligand exchange (e.g., via hydroxyl
groups) whereas p-chi interaction is the predominant mode of ad-
sorption for MCT (41). Whereas MCT is biodegradable and metab-
olized with a half life of 48 h (42), alum is not biodegradable and
may remain at the injection site for years (28, 33, 43). These prop-
erties may affect Ag trafficking and shape the immune responses.
Alum’s potency as an adjuvant is undisputed. However, new
combinations of adjuvants may help tackle areas of unmet need in
emerging diseases or improve efficacy of AIT. Because alum does
not stimulate TLRs, combinations with TLR ligands have been
used to shift the immune response toward Th1 and thereby shorten
the duration of AIT. AITwith MCT and MPLA exists as a shorter-
course therapy option in named-patient products and is subject to
current phase II and phase III clinical studies in the United States
and in Europe (28). Combinations of alum and MPLA (44) or
MCT and MPLA (45) improved Th1 responses in mice and en-
hanced grass pollen IgG1 and IgG4 responses in humans while
reducing IgE responses and the number of AIT injections (46, 47).
Th1 skewing and favorable clinical responses were also observed
following injections of purified ragweed allergen conjugated to
CpG oligonucleotide (48), although long-term benefits could not
be confirmed (32).
MCT is established in AIT (43, 49). However, gaps exist in
comparative in-depth and direct mechanistic studies of MCT in AIT.
Our study demonstrates that MCT has adjuvant properties, making it
a good alternative to alum-based AIT. Of course, murine studies have
limited value with regard to the clinical potential of a novel adjuvant
in human AIT because they use rather unnatural sensitization meth-
ods and because mice are short of biological factors that are con-
sidered important in human AIT (e.g., IgG4) (50, 51). However,
murine studies can contribute to the understanding of the mechanism
by which a novel adjuvant acts. Hence, the fact that MCT could
activate the inflammasome in vitro and that MCT stimulated robust
Ag-specific B and T cell responses in vivo when used as an adjuvant
but these responses came independently of signal transmission
through the inflammasome or TLR should be implied in further de-
sign of MCT-aided vaccination or AIT. Nonetheless, AIT with MCT
stimulated less IgE and IL-4 than AIT with alum. Both MCT and
alum induced high and sustained IgG titers and protection against
anaphylaxis in sensitized mice. Moreover, MCT reduced allergic
adverse events when injected into sensitized mice. This suggests that
MCT may be a suitable and flexible partner for a wide range of AIT
allergens or other vaccines.
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FIGURE 7. Analysis of the role of inflammasome activation on adjuvant
mechanism of action of MCT and alum with regard to stimulation of B and
T cell responses. Wild-type C57BL/6 and ASC knockout mice (n = 5) were
immunized on days 0, 14, and 26 with 0.1 mg OVA on MCT or alum. (A)
Mice were bled on day 42, and OVA-specific IgG1, IgG2b, IgG2c, IgG3,
and IgE Abs were measured by ELISA. The Ab results (mean + SD) are
illustrated as OD measured at a serum dilution of 1:3000. (B) Mice were
euthanized on day 48, and splenocytes were restimulated with OVA (+) or
were not restimulated (2) for analysis of cytokine secretion by ELISA
(mean + SD). The experiment was not repeated.
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